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Mutations in the X-linked gene, methyl-CpG binding protein 2 (Mecp2), underlie a wide range of neuropsychiatric disorders, most
commonly, Rett Syndrome (RTT), a severe autism spectrumdisorder that affects approximately one in 10,000 female live births. Because
mutations in theMecp2 gene occur in the germ cells with onset of neurological symptoms occurring in early childhood, the role ofMeCP2
has been ascribed to brain maturation at a specific developmental window. Here, we show similar kinetics of onset and progression of
RTT-like symptoms inmice, including lethality, ifMeCP2 is removedpostnatally during the developmental stage that coincideswithRTT
onset, or adult stage. For the first time, we show that brains that loseMeCP2 at these two different stages are actively shrinking, resulting
in higher than normal neuronal cell density. Furthermore, we show that mature dendritic arbors of pyramidal neurons are severely
retracted and dendritic spine density is dramatically reduced. In addition, hippocampal astrocytes have significantly less complex
ramified processes. These changes accompany a striking reduction in the levels of several synaptic proteins, including CaMKII /,
AMPA, and NMDA receptors, and the synaptic vesicle proteins Vglut and Synapsin, which represent critical modifiers of synaptic
function and dendritic arbor structure. Importantly, the mRNA levels of these synaptic proteins remains unchanged, suggesting that
MeCP2 likely regulates these synaptic proteins post-transcriptionally, directly or indirectly. Our data suggest a crucial role forMeCP2 in
post-transcriptional regulation of critical synaptic proteins involved in maintaining mature neuronal networks during late stages of
postnatal brain development.
Introduction
Mutations in the X-linked gene methyl-CpG-binding protein 2
(Mecp2) underliemost cases of Rett Syndrome (RTT), a postnatal
progressive neurodevelopmental disorder that manifests in girls
during early childhood. Several mouse models with germline
mutations in Mecp2 have been generated that recapitulate RTT
(Chen et al., 2001,Guy et al., 2001, Shahbazian et al., 2002).Other
studies have indicated that symptomatic MeCP2-null male mice
can be rescued by reactivation of global MeCP2 expression (Gia-
cometti et al., 2007,Guy et al., 2007), suggesting that the neuronal
damage can be reversed. Recently, we and others have shown
that, in addition to neurons, MeCP2-dysfunction in glia also
contributes to RTT (Ballas et al., 2009, Maezawa et al., 2009,
Maezawa and Jin, 2010), specifically to disease progression (Lioy
et al., 2011, Derecki et al., 2012).
In addition to the genetic studies, the impact of MeCP2 dys-
function on brain anatomy as well as neuronal structure and
function has been further supported by several studies indicating
that RTT patients and mice show increased neuronal cell density
(Kishi andMacklis, 2004), reduced brain size (Chen et al., 2001),
reduced dendritic arborization (Armstrong et al., 1995, Kishi and
Macklis, 2004, Ballas et al., 2009), and spine density (Belichenko
et al., 1994).
Although mutations inMecp2 arise in the germline, the onset
of overt neurological symptoms occurs at early postnatal stages
(typically 4–6 weeks of age in male mice) (Chen et al., 2001, Guy
et al., 2001). This has led to the idea, supported most recently by
studies of the critical period in the visual system (Noutel et al.,
2011), that MeCP2 function is required for brain maturation
during a specific developmental window. Yet, whyMeCP2would
be critical at this specific postnatal stage and whether there is a
similar or different functional requirement for MeCP2 past this
stage is poorly understood. A recent study has shown that deple-
tion of MeCP2 in adult male mice results in manifestation of
RTT-like symptoms followed by lethality (McGraw et al., 2011).
However, the underlyingmechanisms of symptom appearance at
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the adult stage were not examined. The present study addresses
these questions.
Specifically, we show that inducible postnatal loss of MeCP2
in mice at two different stages—late juvenile stage, which repre-
sents the time of onset of RTT, or adult stage—results in equal
manifestation of RTT-like symptoms, with immediate onset and
parallel kinetics of symptom progression and lethality. Our anal-
ysis of the brain of symptomatic male mice revealed that postna-
tal loss of MeCP2 in otherwise healthy mice, whether at late
juvenile or adult stage, results in severe abnormalities, which in-
clude global shrinkage of the brain, increased neuronal cell den-
sity, severe retraction of dendritic arbors, reduction in dendritic
spine density, as well as significant reduction in complexity of
astrocytic processes. Importantly, we show that the levels of sev-
eral synaptic proteins, but not the levels of the corresponding
mRNAs, are reduced dramatically, suggesting that MeCP2 likely
regulates these proteins post-transcriptionally, either directly or
indirectly.
Materials andMethods
Animals. All animal studies were approved by the Institutional Animal
Care and Use Committees at Stony Brook University and were in line
with the guidelines established by the National Institutes of Health.
CreER (B6.Cg-Tg(CAG-cre/Esr1)5Amc/J) andMecp2loxB/y (Guy et al.,
2001) (B6;129P2-Mecp2tm1Bird/J) transgenic mice were obtained from
the Jackson Laboratory. CreER (B6.Cg-Tg(CAG-cre/Esr1)5Amc/J) mice
were maintained in a pure C57BL/6 background. The Mecp2loxB/y mice
were backcrossed to C57BL/6 for eight generations. The Mecp2loxJ/y
(Ballas et al., 2001) (B6;129S4-Mecp2tm1Jae/Mmcd) transgenic mice were
obtained from MMRRC and were crossed as mix background. To gen-
erate the double transgenic Mecp2loxJ/y /CreER males, heterozygous
Mecp2loxJ//CreER females, and all their control littermates (WT,CreER,
andMecp2loxJ/y orMecp2loxJ/), we crossed femalemice heterozygous for
the Mecp2-lox allele (Mecp2loxJ/) with male mice heterozygous for the
CreER transgene. A similar strategy was used to generate the Mecp2loxB/y/
CreER males and all the necessary control male mice. The flox and Cre
sequences were identified by PCR on tail biopsies with the following sets
of primers: For Mecp2loxJ allele; forward 5-CAC CAC AGA AGT ACT
ATG ATC-3, reverse 5-CTA GGT AAG AGC TCT TGT TGA-3. For
Mecp2loxB allele; forward 5-TGG TAA AGACCCATG TGACCCAAG-
3, reverse 5-GGC TTG CCA CAT GAC AAG AC-3. For the CreER
allele; forward 5-CCG TAC ACC AAA ATT TGC C-3, reverse 5-ATC
GCG AAC ATC TTC AGG-3.
Tamoxifen treatment. Tamoxifen (Tam; Sigma) was prepared in the
vehicle solution consisting of 10%ethanol/ 90% sunflower oil (Sigma) by
sonication, and aliquots were stored at20°C.Male or femalemice (5 or
10 week old) were injected intraperitoneally with 100mg/kg body weight
of tamoxifen or vehicle (Veh), daily for seven consecutive days. Excision
of theMecp2lox cassette was verified by genotyping of tail biopsies using
the following primers: forward 5-ATG CTG ACA AGC TTT CTT CTA-
3, reverse 5-CAC CAC AGA AGT ACT ATG ATC-3.
Phenotypic scoring and behavioral assays. Male and female mice were
scored weekly or biweekly, respectively. Mice were removed from their
home cage and placed onto a bench, at the same time during the day
when possible. The scoring was performed essentially as previously de-
scribed (Guy et al., 2007), with several modifications. Each of five symp-
toms was scored as 0 (symptom absent), 1 (symptom present), or 2
(symptom severe): Mobility: 0  active without extended freezing pe-
riod. 1  reduced movement and extended freezing period when first
placed on the bench. 2 no spontaneousmovement when placed on the
bench. Gait: 0  as wild-type. 1  hind legs are spread wider than
wild-type or display a “waddling” gait when walking or running. 2 
more severe abnormalities: tremor when feet are lifted, walks backward
or “bunny hops” by lifting both rear feet at once. Hindlimb clasping:
When holding by the tail, mouse was scored 0 legs splayed outwards.
1 one leg is pulled into the body. 2 both legs are pulled touching each
other or touching the body. Tremor: Mouse observed while standing on
the flat palm of the hand. 0 no tremor. 1 intermittent mild tremor.
2  continuous tremor or intermittent violent tremor. General condi-
tion: 0 clean shiny coat, clear eyes, normal stance. 1 eyes dull, coat
dull/ungroomed. 2  eyes crusted or narrowed, piloerection, hunched
posture or fur loss and self-injury.Micewere alsoweighed at each scoring
session.
Behavioral assays. For all behavioral studies, the observer was blinded
to genotype.
Digiscan activity monitor. The mouse was placed in the center of an
empty rat cage (44  21 cm) situated inside an Opto-Varimex-Minor
animal activity meter (Columbus Instruments). Fifteen  15 infrared
beams running in the x/y coordinates and 2 cm above the base of the
machine recorded beambreaks associatedwith ambulatory activity (con-
secutive beam breaks) and total activity (all beam interruptions) during
the 20 min observation period.
Rotarod. Mice were tested on a Medical Associates (model ENV-
575M) Rotarod and ran by the “rotarod” program on a Dell Optiplex
with aWindows 98 operating platform. The apparatus was amechanized
30-cm-long rod divided into five 6 cm sections by four plastic white discs.
The speed of rotation increased from4 rpm to 40 rpm through the course
of 5 min session. The latency in seconds to drop off the rotarod was the
main dependent measure of motor competence. Each mouse was tested
for three consecutive trials with a 10 min rest between each session.
Wire hang test. The mice were placed on a 44 cm long stainless steel
wire suspended 54 cm off the ground by two wooden posts so that only
their front paws contact the wire. The latency to fall onto a foam pad
below the apparatus was recorded. The maximum hang time was 60 s
before removal. Each mouse was tested on three consecutive trials with-
out resting.
Dowel assay. The tested mouse was placed in the middle of a wooden
dowel (diameter, 1 cm; length, 16 cm, 30 cm above the ground) and was
allowed to move freely. The latency to fall was measured for a maximum
time of 2 min.
RNA isolation and quantitative real-time PCR analysis. Total RNA was
prepared from tissue using TRIZOL Reagent (Invitrogen) and treated
with RNase-free DNase (Ambion, DNA-free kit). For reverse transcrip-
tion, AMV-RT (New England BioLabs) was used and quantitative real-
time RT-PCR was performed in an ABI StepOnePlus real-time PCR
system using SYBR-green PCR master mix (Applied Biosystems). The
relative abundance of the specific mRNAs was normalized to -actin
mRNA. The specific primers used were as follows: Mecp2, forward 5-
AGG CAGGCA AAGCAG AAA CAT CAG-3 and reverse 5-TCA TAC
TTT CCAGCAGAT CGGCCA-3; -actin, forward 5-GGC TGT ATT
CCC CTC CAT CG-3 and reverse 5-CCA GTT GGT AAC AAT GCC
ATG T-3; for Synaptotagmin 1, forward 5-GAA CTG CAT AAA ATC
CCA TTG CC-3 and reverse 5-CAG CAG GTC ACG ACT AGA AGG-
3; Vglut1, forward 5-CCG GCA GGA GGA GTT TCG GAA G-3 and
reverse 5-GTG CAG TCC ACC ACA GGC GG-3; PSD-93, forward
5-CTT GTG CAT GTG TCG GAA AAG-3 and reverse 5-TCA GAG
GAG AGA TGT GAG ACT G-3; CaMKII, forward 5-CGT TTC ACC
GACGAG TAC CAG-3 and reverse 5-GCG TAC AATGTTGGA ATG
CTT C-3; CaMKII, forward 5-CGC ATC TGC CGC TTG TT-3 and
reverse 5-TCC TCG GAG ATG CTG TCA TG-3; NMDAR2A, forward
5-AGC CCC CTT CGT CAT CGT AGA-3 and reverse 5-ACC CCT
TGC AGC ACT TCT TCA C-3; GABABR2, forward 5-ATG CAA TAA
AGT ATG GGC CGA A-3 and reverse 5-CGC GAT GAT AGA GGT
GAC AGA-3; for GluR2, forward 5-TTC TCC TGT TTT ATG GGG
ACT GA-3 and reverse 5-CCC TAC CCG AAA TGC ACT GTA-3;
GluR3, forward 5-GTG CAG TTA TAC AAC ACC AAC CA-3 and
reverse 5-GAG CAG AAA GCA TTA GTC ACA GA-3.
Western blot analysis. Protein extracts were prepared from different
parts of the brain using themodifiedDignammethod (Ballas et al., 2009).
Tissues were homogenized in a Dounce homogenizer with the loose
pestle, directly in high-salt lysis buffer. For whole-brain extract, tissues
were homogenized in aDounce homogenizerwith the loose pestle in lysis
buffer containing 5 mM sodium phosphate, pH 7.2, 320 mM sucrose, 1
mM sodium fluoride, and 1 mM sodium orthovanadate and protease
inhibitors (Roche). The lysates were centrifuged at 4°C for 15 min at
700  g. Supernatants were collected and Western blotting was per-
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Figure 1. MeCP2 protein is efficiently depleted in brains ofMecp2loxJ/y/CreERmice injectedwith Tamoxifen at 5 or 10weeks of age.A, Top, Schematic diagram showing the Tam-induced excision
of the floxedMecp2 cassette using the Jaenisch (J)Mecp2-loxmouse line and the CreERmouse line. Bottom, Schematic diagram showing the time period of onset and progression of RTT symptoms
in male mice with germline mutations in Mecp2 and the postnatal stages at which Mecp2 was inactivated upon Tam injections. Red arrows indicate the age of the mice when first injected with
tamoxifen.B, Representative images of immunostainingof brain sections of 5W-Tam-or Veh-injectedMecp2loxJ/y/CreERmice immunolabeled forMeCP2 (green) andNeuN (red), 19weeks after Tam
(T) or Veh (V) injection. Note thatMeCP2 (green) is absent inmost neurons (NeuN, red) and astrocytes (GFAP, red) in the cortex and hippocampus of the Tam-injectedmice, respectively. Scale
bars: left panels, 100m; right panels, 20m. C, E, Representative images of the dentate gyrus area of 5W- (C) or 10W- (E) Tam- or Veh-injectedMecp2loxJ/y/CreERmice immunolabeled forMeCP2
(green), and NeuN (red). DAPI (blue) represents nuclear staining. Scale bar, 50m.D, F, QuantitativeWestern blot showing the levels of MeCP2 in the indicated brain areas of 5W- (D) or 10W- (F )
Tam or Veh-injected Mecp2loxJ/y/CreER mice and Tam-injected Mecp2loxJ/y mice. Actin served as loading control. All mice were analyzed 18 weeks after injection. One-way ANOVA followed by
appropriate post hoc for multiple-comparisons test was used to determine differences between groups. Error bars are mean SEM *p 0.05. n 3 mice per genotype.
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formed as described previously (Ballas et al.,
2009). The primary antibodies used are as fol-
lows: chicken anti-MeCP2 antibody (a gener-
ous gift from J.M. LaSalle, University of
California, Davis, Davis, CA) (1:10,000) or a
mouse anti-MeCP2 (Sigma) (1:2000), mouse
anti-CaMKII (Millipore) (1:2000), rabbit
anti-CaMKII (Abcam) (1:5000), rabbit anti-
GluR2/3 (Millipore) (1:500), mouse anti-
GABABR2 (Neuromab) (1:2000), mouse
anti-Vglut1 (Neuromab) (1:250), rabbit
anti-NMDAR2A (Abcam) (1:200), mouse
anti-PSD-93 (Neuromab) (1:500), rabbit anti-
Synaptotagmin 1 (Synaptic Systems) (1:1000),
rabbit anti-synapsin 1 (Abcam) (1:1000), mouse
anti-PSD-95 (Neuromab) (1:1000), and rabbit
anti- actin (Abcam) (1:2000)was used for load-
ing control. The secondary antibodies used were
IRDye800 or IRDye700 conjugated (LI-COR
Biosciences) (1:10,000). Membranes were
scanned using the Odyssey-Infrared Imaging
System (LI-CORBiosciences), and the intensities
of thebandsof interestweredetermined fromthe
captured images using the Odyssey imaging
software.
Immunohistochemistry. Mice were fixed by
transcardial perfusion with PBS-buffered 4%
paraformaldehyde as described previously (Bal-
las et al., 2009). Briefly, brains were removed and
postfixed overnight with PBS-buffered 4% para-
formaldehyde at 4°C. The fixed tissue was cryo-
protected with 30% sucrose in PBS buffer and
frozen in optimal cutting medium (Neg50,
Richard-Allan Scientific). Coronal sections were
obtained by sectioning the tissue on a HM505E
MicromCryostat (Cryostat Industries) at 40m
and preserved at 20°C in PBS-buffered 50%
glycerol until analyzed. The sectionswere immu-
nostained using rabbit anti-MeCP2 antibody (a
generous gift from M. Greenberg, Harvard
Medical School, Boston, MA) (1:500), chicken
anti-GFAP (Millipore Bioscience Research Re-
agents) (1:500), or mouse anti-NeuN (Milli-
pore Bioscience Research Reagents) (1:150)
followed by incubation with the appropriate
secondary antibodies conjugated to cyanine
(Jackson ImmunoResearch). MeCP2 immuno-
staining was enhanced using biotinstreptavidin-
conjugated secondary antibodies. Images were
collected on a Zeiss confocal laser-scanning LSM
510microscope.
Nissl staining. Brains were harvested and
sectioned as described above. Consecutive cor-
onal sections (40 m) were mounted on
gelatin-coated slides, rehydrated, stained with
cresyl violet dye (Sigma), andmounted on cov-
erslips with DPX. Images were taken with a
Zeiss Axioskop microscope with SPOT soft-
ware (Diagnostic Instrument). To measure the
thickness of the pyramidal layer of the CA1 re-
gion of the hippocampus and the density of
cells in layer V of the cortex, images of several sections from each animal
(n 3) were analyzed using the ImageJ software. Five differentmeasure-
ments were performed along the pyramidal layer of the CA1 region for
each image. The number of cells present in each image of the Layer V
were counted and normalized per square micrometer.
Golgi staining. Golgi staining was performed using a modified Golgi
method (EZ Golgi method, Weill Cornell Medical College, New York,
NY) and performed according to the manufacturer’s instructions. Three
brains of Veh- or Tam-injectedMeCP2loxJ/y/CreERmice were incubated
in the impregnation solution and sectioned at a thickness of 150 m.
Sixteen to seventeen pyramidal neurons in the CA1 region of the hip-
pocampus and 15 astrocytes located between the myelinated fibers and
the compacted neuronal cell body layers of the CA1 region were traced
and reconstructed using a camera lucida device blinded to genotype and
treatment. Reconstructed neurons and astrocytes were analyzed using
Neurolucida explorer software. For Sholl analysis (Sholl, 1953), the con-
Figure 2. The loss of MeCP2 at late juvenile or adult stages induces RTT-like phenotypes in male and female mice. A, B,
Phenotypic scores and Kaplan–Meier survival time course, respectively, of 5W-Tam-injectedMecp2loxJ/y/CreER and the indicated
control mice. The number of mice in B is similar to the indicated in A. D, E, Phenotypic scores and Kaplan–Meier survival time
course, respectively, of 5W-Tam-injectedMecp2loxB/y/CreERand the indicated controlmice. Thenumber ofmice inE is similar to the
indicated in D. G,H, Phenotypic scores and weight gain time course, respectively, of 5W-Tam-injectedMecp2loxJ//CreER female
mice and the indicated controlmice. Thenumber ofmice inH is similar toG. J,K, Phenotypic scores andKaplan–Meier survival time
course graphs, respectively, of 10W-Tam-injected Mecp2loxJ/y/CreER and the indicated control mice. The number of mice in K is
similar to the indicated in J. M, Overlay of the aggregate symptom scores from the time of injection of the 5W-Tam-injected
Mecp2loxJ/y/CreER and the 10W-Tam-injected Mecp2loxJ/y/CreER mice. Inset shows no significant differences in the mean of the
trend slopes between the5W-and10W-Tam-injectedmice (NS,p0.05). Error bars aremean SEM. t testwas used to compare
within the 5W- and the 10W-Tam-injected groups.N, Overlay of the survival curves of the 5W- and 10W-Tam-injectedMecp2loxJ/
y/CreERmice. A LogRank survival test showed no significant difference between the survival time of the 5W- and the 10W-Tam-
injectedMecp2loxJ/y/CreERmice. Inset shows no significant differences in themean age of death between the 5W- and 10W-Tam-
injectedmice (NS, p 0.05). Error bars are mean SEM. t test was used to compare within the 5W- and the 10W-Tam-injected
groups. C, F, I, L, Images illustrating the hindlimb clasping phenotype of the indicated Tam-injected MeCP2loxJ/CreER or Tam-
injectedMeCP2loxB/CreERmice. Note that the Tam-injectedMeCP2loxJ/y/CreERmice (male and female) are overweight and that the
female is injured due to overgrooming (white arrow). All the mice in the images were injected with Tam at 5 weeks of age except
in L, where the mouse was injected at 10 weeks of age (10 W). Red arrows show the time of Tam or Veh injection.
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centric circles were 10m. Dendritic spines were counted along 100m
lengths.
Brain-weight assessment.Micewere anesthetized at the appropriate age
with isoflurane, and the brains were harvested and immediately
weighted. Whole brains were excised by a single cut at the caudal edge of
the cerebellum between the brain and the spinal cord.
Results
Inducible loss of MeCP2 in late juvenile or adult mice results
in severe RTT-like phenotype with similar kinetics of
symptom initiation and progression
To induce MeCP2 loss at specific postnatal stages, we crossed a
transgenicmouse line carrying aTam-inducibleCre recombinase
(CreER) transgene driven by the ubiquitous CMV/-actin pro-
moter with a mouse line carrying floxedMecp2 allele (Mecp2loxJ)
(Chen et al., 2001), which generate mutation in Mecp2 upon
excision of the loxP cassette (Fig. 1A, top).Male progeny harbor-
ing the CreER and the Mecp2lox alleles (Mecp2loxJ/y/CreER) were
injected with Tam for seven consecutive days starting at two dif-
ferent time points: (1) a late juvenile stage (5 week old, referred to
as 5W-Tam injected), a time at which the brain is still growing
and developing and that parallels the time period of onset of RTT
symptoms in male mice with germline
mutation inMecp2 (Chen et al., 2001, Guy
et al., 2001); or (2) an adult stage (10 week
old, referred to as 10W-Tam injected),
where the brain has matured in term of
reaching its full size and dendritic com-
plexity (Fig. 1A, bottom).We determined
the efficiency of the floxedMecp2 excision
and found that MeCP2 was undetectable
by immunostaining in most neurons and
astrocytes in brains of 5W-Tam-injected
Mecp2loxJ/y/CreERmice (Fig. 1B,C). Quan-
titative Western blot analysis showed 80–
90% reduction in the MeCP2 protein
content in all areas of the brain including
cortex, hippocampus, cerebellum, and
brainstem regions (Fig. 1D). Importantly,
Mecp2-lox excision in the 10W-Tam-
injectedMecp2loxJ/y/CreERmice was as effi-
cient as in the 5W-Tam-injectedMecp2loxJ/y/
CreER mice under the same conditions
(Fig. 1E,F), allowing a direct and unbi-
ased comparison of the effect of MeCP2
loss at the late juvenile and adult stages.
We first analyzed whether MeCP2
loss-of-function at a late juvenile stage, in
otherwise normal healthy brain, could
cause overt RTT-like phenotypes charac-
teristic of the corresponding germline
Mecp2-null mouse model (Mecp2J/y)
(Chen et al., 2001) and the kinetics of the
appearance of symptoms.Weused the ob-
servational phenotypic scoring system
(0–10) described previously (Guy et al.,
2007) for five typical phenotypes mani-
fested in germline MeCP2-null mice,
which we termed as classic RTT: mobility,
gait, hindlimb clasping, tremors, and gen-
eral condition. Weekly scoring of the
Tam-injected Mecp2loxJ/y/CreER progeny
showed dramatic progression of aggregate
symptom scores including all five catego-
ries, beginning as early as 1 week after the last Tam injection and
reaching amean score of 8 at 18 weeks after injection followed by
lethality, with 50% survival at 16 weeks after Tam injection (Fig.
2A–C). Veh-injected Mecp2loxJ/y/CreER mice and all other Tam-
injected controlmice remained equally healthy (Fig. 2A–C). Sim-
ilar results were obtained when a different floxed Mecp2 mouse
line (Guy et al., 2001) was used to generate Tam-inducible
Mecp2loxB/CreER mice (Fig. 2D–F), suggesting that the severe
RTT phenotype observed was related directly to the functional
loss of MeCP2 and not dependent on the specific mouse line or
type of Mecp2 mutation generated upon Cre excision. Further-
more, the phenotypic deficits were similar to those observed in
mice with germline mutation inMecp2 (classic RTT). These data
show that RTT-like phenotypes can be initiated and efficiently
progressed as soon as Mecp2 is mutated at 5 weeks of age, a
postnatal stage, which coincides with the onset of classic RTT in
male mice.
Because human RTT affects mostly girls, we sought to deter-
mine whether the loss of MeCP2 in heterozygous female mice at
a late juvenile stage could also initiate RTT-like phenotypes. The
5W-Tam-injected Mecp2loxJ//CreER female mice showed effi-
Figure 3. Mice that lost MeCP2 at a late juvenile or adult stage show similar behavioral deficits. Male and female mice were
subjected for the indicated behavioral tests at 13weeks or 27weeks after injection, respectively.A–K, Total activity test in digiscan
activity monitor (A–C), wire-hang test (D–F), rotarod test (G–I), and dowel test (J, K). The colors of the graphs and bar graphs
correspond to the indicated genotypes in the right bottom corner.A,D,G, J, 5W-Tam-injectedMecp2loxJ/y/CreER and the indicated
control mice. B, E, H, K, 5W-Tam-injected Mecp2loxJ//CreER and the indicated control female mice. C, F, I, 10W-Tam-injected
Mecp2loxJ/y/CreER and the indicated control malemice. The number ofmice inD andG is similar to that indicated inA; in E andH it
is similar to B; in F and I it is similar to C. Note that one outlier 10W-Tam-injectedMecp2loxJ/y/CreERmouse whose score wasmore
than two SDs from the groupmeanwas removed from the rotarod analysis in I. One-way ANOVA followed by appropriate post hoc
for multiple-comparisons test was used to determine differences between groups. Error bars are mean  SEM. *p  0.05
represents significant differences between the different Tam-injected Mecp2loxJ/CreER mouse groups and all control littermate
groups.
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cient excisionwith up to 50% reduction in
Mecp2mRNA (data not shown). Biweekly
scoring of the Tam-injected Mecp2loxJ//
CreER mice showed that, unlike in the
male mice, the onset of symptoms ap-
peared 16 weeks after Tam injection,
reaching an average score of 5–6 at 22
weeks postinjection followed by stabiliza-
tion of the symptoms (Fig. 2G). All other
control mice remained healthy through-
out the period analyzed (Fig. 2G). None of
the Tam-injectedMecp2loxJ//CreERmice
died, but 4 of 8mice had to be killed due to
a severe self-injurious overgrooming (Fig.
2 I, right image), a repetitive autistic-like
behavior. Furthermore, female mice be-
came extremely obese with up to 100%
increase in body weight (Fig. 2H; I, left
image). The delayed onset and the slow
kinetics of the appearance of symptoms
followed by their stabilization, as well as
the type of symptoms, are closely corre-
lated with the classic form of RTT in fe-
malemice (Mecp2/) (Chen et al., 2001).
Next, we examined the effect of
MeCP2 loss at the adult stage, when the
brain is mature and has attained its full
size. For this,Mecp2loxJ/y/CreERmice were
injected with Tam at 10 weeks of age, and
analyzed for overt RTT-like symptoms.
Our data show, that like the juvenilemice,
adultmice also developedRTT-like symp-
toms beginning as early as 1 week after the
last Tam injection and reaching an aver-
age score of 8, 16 weeks from injection
(Fig. 2 J,L). Furthermore, like the juvenile
mice, the Tam-injected adultmice all died
by 21 weeks after injection with 50% sur-
vival at 16–17 weeks after Tam injection
(Fig. 2K). The inducible loss of MeCP2 at
late juvenile andadult stages (Fig. 1) allowed
us to directly compare the effect of MeCP2
loss at the two different developmental
stages. Surprisingly, comparison of the ki-
netics of symptom progression and the
survival rate from the time of Tam injec-
tion showed no significant differences
between juvenile and adult mice (Fig. 2M,N), suggesting similar
and absolute requirement forMeCP2 at the critical stage of brain
maturation (late juvenile) and after, when the brain is already
mature (adult).
We further compared the Tam-injected juvenile and adult male
mice for behavioral deficits at 13 weeks after injection, a stage when
theywere not severely symptomatic but reached amedian score of 6
(Fig. 2M). We found that the total activity in a digiscan activity
monitor of the 5W- and 10W-Tam-injectedMecp2loxJ/y/CreERmice
was reduced by 40–50% relative to all other control mice (Fig.
3A,C). In a wire hang test, the 5W- and the 10W-Tam-injected
Mecp2loxJ/y/CreER mice showed altered forelimb strength with
shorter latency to fall (Fig. 3D,F), and their motor coordination
evaluated on an accelerating rotarod was impaired, as evident by
their short latency to fall (Fig. 3G,I).Wealsoevaluated the5W-Tam-
injected heterozygous femalemice at 27weeks after Tam injection, a
stagewhen their symptoms stabilized and reached amean score of 6,
and found poor performance in all tests (Fig. 3, compare B,E,H,K,
A,D,G,J). In fact, the female mice performed worse than the male
mice, likely due to their severe obesity. These behavioral deficits are
comparable to the known behavioral deficits in classic RTT (Ricceri
et al., 2008).
Inducible loss of MeCP2 at late juvenile or adult stage causes
global brain shrinkage and compaction of neuronal cell
bodies
To understand the underlying cause of RTT-like phenotype and
behavioral deficits in mice that lost MeCP2 at a late juvenile or
adult stage, we analyzed in depth the anatomy of the brain of the
symptomaticmice and themorphology of their neurons and glia.
Because in our mouse models the brain was similar in size to the
wild-type brain at the time of Tam injection, we first asked
Figure 4. The loss ofMeCP2 at late juvenile or adult stage leads to shrinkage of the brain.A,B, Representative images showing
that symptomaticMecp2loxJ/y/CreERmice (loxJ/y/CreT), injected with Tam at 5 (A) or 10 (B) weeks of age, have smaller brains
than their control littermates,Mecp2loxJ/yT (loxJ/yT) andMecp2loxJ/y/CreERV (loxJ/y/CreV) mice. Brains are frommice at
16 weeks after injection. C, D, Age-dependent changes in brain weights of WT, 5W- (C) or 10W- (D) Tam- or Veh-injected
Mecp2loxJ/y/CreER and Mecp2loxJ/y mice. Fragmented lines distinguish between the brains that are smaller (below) or bigger
(above) than the Mecp2loxJ/y/CreER brains right after the last Tam injection (6W or 11W). E, Brains of the 5W-Tam-injected
Mecp2loxJ/y/CreERmice are smaller than their control littermates at 24weeks of age (18weeks after injection), and smaller than the
WT brains at 5 weeks of age and the 5W-Tam-injectedMecp2loxJ/y/CreER at 6 weeks of age (after the last Tam injection). F, Brains
of the 10W-Tam-injected Mecp2loxJ/y/CreER mice are smaller than the brains of the 10W-Veh-injected Mecp2loxJ/y/CreER mice at
29–32weeks of age (18–21weeks after injection) and smaller than theWT brains at 10weeks of age and the 10W-Tam-injected
Mecp2loxJ/y/CreER brains at 11 weeks of age (after the last Tam injection). G, Brains of the 5W-Tam-injected Mecp2loxJ//CreER
female mice are smaller than the brains of their control littermates at 39–50 and 79–99 weeks of age. Two-way ANOVA analysis
followed by appropriate post hoc for multiple-comparison tests were performed to determine differences between Veh/Tam
groups and between the different age groups. Error bars are mean SEM. *p 0.05. n 4–6 mice per genotype. H, I, Time
course analysis of body weight gain of 5W- (H ) or 10W- (I ) Tam-injectedMecp2loxJ/y/CreERmice and the indicated control male
mice. n indicates the number of mice used. Red arrows indicate the time of Tam or Veh injection.
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whether the loss of MeCP2 would negatively affect the brain size.
Unexpectedly, we found that the loss of MeCP2 upon Tam treat-
ment of Mecp2loxJ/y/CreER mice, whether at a late juvenile or
adult stage, both resulted in significantly reduced brain size when
compared with Veh-injected Mecp2loxJ/y/CreER or Tam-injected
Mecp2loxJ/y age-matched littermates (Fig. 4A,B). Time course
analysis of normal brains from wild-type mice showed that the
brain reaches its full size only at	10weeks of age (Fig. 4C). Thus,
Tam injection at 5 or 10 weeks of age represents two different
developmental stages in termsof globalbrainmaturation. 5W-Tam-
injectedMecp2loxJ/y/CreER mice, like all other control male mice,
had similar brain weights by the end of the seventh consecutive
injection (Fig. 4E, 6 weeks of age). However, at 24 weeks of age
(18 weeks after injection), while the size of the brains of all con-
trol mice were similar and significantly larger than the brain size
of the correspondingmice at 6weeks of age (Fig. 4C,E), the brains
of the Tam-injected Mecp2loxJ/y/CreER mice were significantly
smaller (by 10%) than the brains of all controlmice at 24weeks of
age (Fig. 4C,E). In fact, at 24 weeks of age, the brains of the
symptomatic 5W-Tam-injected Mecp2loxJ/y/CreER mice were
Figure 5. The brain anatomy is severely affected upon the loss ofMeCP2 at a late juvenile or adult stage.A,B, Images of Nissl staining showing smaller brain structures for the 5W- (A) and 10W-
(B) Tam-injected mice at 24 and 30 weeks of age, respectively, when compared with their control Veh-injected littermates. CTX, Cortex; LV, lateral ventricle; HP, hippocampus; TH, thalamus; HY,
hypothalamus. Scale bars, 800m. C,D, Representative images of Nissl staining showing smaller hippocampal structure for the 5W- (C) and 10W- (D) Tam-injectedmice. DG, Dentate gyrus. Scale
bars, 400m.E,F, The cell bodies of the pyramidal (Py) neurons in the CA1 area of the hippocampus of the 5W- (E) and10W- (F ) Tam-injectedMecp2loxJ/y/CreERmice aremore compact. so, Stratum
oriens; py, pyramidal layer; sr, radiatum. Scale bars, 20m. G,H, The thickness of the pyramidal neuronal cell bodies in the CA1 area of the 5W- (G) and 10W- (H ) Tam-injectedMecp2loxJ/y/CreER
mice is significantly reduced. I, J, Representative images of Nissl staining showing a higher density of neuronal cell bodies in layer V of themotor cortex of the 5W- (I ) or 10W- (J ) Tam-injectedmice
when compared with 5W- or 10W-Veh-injectedMecp2loxJ/y/CreERmice. Scale bars, 40m. K, L, The density of the neurons in layer V of themotor cortex of 5W-(K ) and the 10W- (L) Tam-injected
Mecp2loxJ/y/CreERmice is significantly higher than the Veh-injected control mice. t test was used to compare within Veh and Tam groups. Error bars are mean SEM. *p 0.05. n 3 mice per
genotype.
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even smaller (by 5%) than the normal wild-type brains at 5 weeks
of age, the starting point of Tam injections, and smaller than all
other control mice right after the last Tam injection (6 weeks of
age) (Fig. 4C,E). These results suggest that the reduced brain size
is likely caused, at least in part, by shrinkage of the developing
brain. This phenomenon is even more noticeable in brains of
symptomatic Mecp2loxJ/y/CreER mice treated with Tam at 10
weeks of age, a time bywhich the normal brain reaches its full size.
Figure 6. Dendritic complexity of hippocampal pyramidal neurons is severely affected upon the loss of MeCP2 at late juvenile stage. A, Representative Camera lucida tracing of CA1 pyramidal
neurons in the hippocampus of symptomatic 5W-Tam-injectedMecp2loxJ/y/CreER and the 5W-Veh-injectedMecp2loxJ/y/CreER control littermate mice. Concentric circles for Sholl analysis in 10m
radius increments are superimposed in red. Scale bars, 40m. B, E, Sholl analysis of the 5W-Tam-injectedmice showing that the basal (B) and apical (E) dendrites of CA1 pyramidal neurons at 18
weeks after the last Tam injection (24weeks of age) are significantly less complex than those of the 5W-Veh-injectedMecp2loxJ/y/CreER age-matched littermatemice and even less complex than the
dendrites of Tam-injected mice right after the last injection (6 weeks of age). Two-way repeated-measures ANOVA followed by appropriate post hoc for multiple-comparisons test was used to
determine differences within Veh and Tam groups at 18 weeks after injection or within 0 and 18 weeks after the last Tam injection of 5W-Tam-injected Mecp2loxJ/y/CreER mice. C, D, F, G, CA1
pyramidal neurons of 5W-Tam-injectedMecp2loxJ/y/CreERmice exhibit fewer and shorter basal (C,D) and apical (F,G) dendritic branches at 18weeks after Tam injection.Mann andWhitney testwas
used to comparewithin Veh and Tamgroups at 18weeks after injection orwithin the 5W-Tam-injectedMecp2loxJ/y/CreERmice at 0 and 18weeks after injection.H, Representative images of Camera
lucida tracing of CA1pyramidal neurons in thehippocampus showing structural abnormalities in spines and the associated secondary dendrites of the 5W-Tam-injectedMecp2loxJ/y/CreERmicewhen
comparedwith Veh-injectedMecp2loxJ/y/CreER or Tam-injectedwild-type (WT)mice, 18weeks after injection. Arrows indicate swelling or thickening of the associated dendritic branches. Scale bars,
2 m. I, CA1 pyramidal neurons of 5W-Tam-injected Mecp2loxJ/y/CreER mice demonstrate significant reduction in dendritic spine density. Spine density per 100 m length was measured on
secondary dendrites. One-way ANOVA followed by appropriate post hoc for multiple-comparison tests was used to determine differences between groups. Error bars are mean SEM. *p 0.05
significant differences in dendritic complexity of the 5W-Tam-injected Mecp2loxJ/y/CreER at 0 and 18 weeks after the last injection. #p 0.05 significant differences between 5W-Tam and
Veh-injectedMecp2loxJ/y/CreERmice at 24 weeks of age (18 weeks after injection). n 3 mice per genotype and age. n 5–6 neurons per animal.
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Indeed, the brains of all control mice as well as the Tam-injected
Mecp2loxJ/y/CreERmice were similar in size right after injection of
Veh or Tam (11 weeks of age) and similar to the brain size of the
control mice at 28–32 weeks of age (Fig. 4D,F). However, at
28–32 weeks of age, the brain size of symptomatic 10W-Tam-
injected Mecp2loxJ/y/CreER mice was reduced by 10% relative to
the brain size of the different control mice or to the brain size of
the sameMecp2loxJ/y/CreERmice right after injection (Fig. 4D,F).
To verify that the reduced brain size of symptomatic 5W- or
10W-Tam-injected Mecp2loxJ/y/CreER mice is brain specific and
not due to simply reduced body size, we analyzed the bodyweight
from the time of injection to their severe symptomatic period.
This analysis revealed that in fact the 5W-
or 10W-Tam-injected Mecp2loxJ/y mice
were somewhat overweight compared
with all other control littermatemice (Fig.
4H, I). The body weight gain was previ-
ously reportedwith the samemutation in
male mice with classic RTT (Chen et al.,
2001). Remarkably, similar to the males,
the brains of the 5W-Tam-injected
Mecp2loxJ//CreER heterozygous female
mice, which were extremely obese at their
symptomatic stage (Fig. 2G–I), were also
reduced in size by 10% (Fig. 4G). This
suggests that even though MeCP2 loss is
mosaic and occurs only in 50% of the cells
at most, the effect on the anatomy of the
female brain is global. Together, these
data strongly suggest that postnatal loss of
MeCP2, whether at late juvenile or adult
stage, elicited shrinkage of the mature
healthy brain in hemizygous males as well
as in heterozygous females.
Analysis of the histology of the brains
of the 5W- and 10W-Tam-injected
Mecp2loxJ/y/CreER mice showed global
shrinkage of the brain with no other de-
tectable malformations (Fig. 5A,B). De-
tailed analysis of the hippocampus
showed overall shrinkage of all areas, in-
cluding CA1, CA2, CA3, and the dentate
gyrus, of both 5W- and 10W-Tam-
injected Mecp2loxJ/y/CreER mice in their
symptomatic stage compared with the
hippocampus of Veh-injectedMecp2loxJ/y/
CreER littermate mice (Fig. 5C,D). Fur-
thermore, the thickness of the pyramidal
layer of CA1 area in the symptomatic brains
was significantly reduced (up to 30%), and
neuronal cell bodies appearedmore compact
(Fig. 5E–H).Thecortical areaof symptomatic
5W-and 10W-Tam-injected Mecp2loxJ/y/
CreER mice was affected similarly with 10–
15% higher cell density than in the cortex
(layer V) of Veh-injected Mecp2loxJ/y/CreER
mice (Fig. 5I–L).
The loss of MeCP2 at late juvenile or
adult stage induces retraction of
dendritic arbor structures of mature
neurons and reduces the complexity of
astrocytic processes
Next, we analyzed the morphology of the pyramidal neurons in
the CA1 area of the hippocampus in mice that lost MeCP2 at a
late juvenile or adult stage. For this, we evaluated the hippocampal
dendritic complexity of symptomatic Tam-injected Mecp2loxJ/y/
CreERmice, 18 weeks after injection, using Golgi impregnation.
Interestingly, comparison of the CA1 pyramidal neurons of the
5W-Veh- and Tam-injected Mecp2loxJ/y/CreER mice revealed that
the Tam-injected Mecp2loxJ/y/CreER mice developed severe den-
dritic anomalies (Fig. 6A). While the number of primary den-
drites was unchanged, Sholl and branch analyses showed that the
pyramidal neurons of Tam-injected Mecp2loxJ/y/CreER mice ex-
hibited fewer and shorter basal and apical dendritic branches when
Figure7. The loss ofMeCP2at adult stage induces reduction indendritic complexity and spinedensity.A,D, Sholl analysis of the
10W-Tam-injected mice showing that the basal (A) and apical (D) dendrites of CA1 pyramidal neurons at 29 weeks of age (18
weeks after Tam injection) are significantly less complex than those of 11weeks of age (right after the last Tam injection) and less
complex than the dendrites of the 10W-Veh-injected Mecp2loxJ/y/CreER age-matched littermates. Two-way repeated-measures
ANOVA followed by appropriate post hoc for multiple-comparisons test was used to determine differences within Veh and Tam
groups at 18 weeks after injection or within 0 and 18 weeks after the last Tam injection of 10W-Tam-injected Mecp2loxJ/y/CreER
mice.B,C, E, F, The CA1 pyramidal neurons of 10W-Tam-injectedMecp2loxJ/y/CreERmice exhibit fewer and shorter basal (B, C) and
apical (E, F ) dendritic branches at 29weeks of age (18weeks after injection). Mann andWhitney test was used to comparewithin
Veh and Tam groups at 18 weeks after injection or within the 10W-Tam-injectedMecp2loxJ/y/CreERmice at 0 and 18 weeks after
injection. G, Representative images of Camera lucida tracing of CA1 pyramidal neurons in the hippocampus showing structural
abnormalities in spines and the associated secondary dendrites of the 10W-Tam-injectedMecp2loxJ/y CreERmice when compared
with Veh-injected Mecp2loxJ/y/CreER mice, 18 weeks after injection. Arrows indicate swelling or thickening of the associated
dendritic branches. Scale bars, 2m.H, CA1 pyramidal neurons of 10W-Tam-injectedMecp2loxJ/y/CreERmice demonstrate signif-
icant reduction in dendritic spine density. Spine density per 100m lengthwasmeasured on secondary dendrites. t test was used
to compare within Veh and Tam groups. Error bars are mean SEM. *p 0.05 significant differences in dendritic complexity of
the 10W-Tam-injected Mecp2loxJ/y/CreER at 0 and 18 weeks after the last injection. #p 0.05 significant differences between
10W-TamandVeh-injectedMecp2loxJ/y/CreERmiceat29weeksof age (18weeksafter injection).n3micepergenotypeandage.
n 5–6 neurons per animal.
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compared with Veh-injected Mecp2loxJ/y/
CreER littermates at 24 weeks of age (18
weeks after injection) (Fig. 6A–G). Such
abnormalities in dendritic arbor structure
were previously found in humanRTT and
RTT mouse models with germline muta-
tions in MeCP2 (Armstrong et al., 1995,
Kishi and Macklis, 2004, Ballas et al.,
2009). Potentially, these differences in
dendritic arbors could be due to develop-
mental stagnation, but they could also be
caused by retraction of dendritic arbors.
The ability to induce postnatal loss of
MeCP2 in our mouse model allowed us
to distinguish between these two possi-
bilities. For this, we analyzed the den-
dritic complexity of 5W-Tam-injected
Mecp2loxJ/y/CreERmice immediately after
the last Tam injection (6 weeks of age). At
this time,MeCP2was still present, butwas
reduced by 30–40% of its normal level
(data not shown), and the mice appeared
healthy (Fig. 2A). Comparison of the den-
dritic complexity of the Tam-injected
Mecp2loxJ/y/CreER mice at 6 weeks of age
and of the Veh-injectedMecp2loxJ/y/CreER
mice at 24 weeks of age indicated that the
dendritic complexities of the pyramidal
neurons are largely similar to each other
except for the basal dendritic branches
closer to the soma, which seemed less
complex in the 6-week-old Tam-injected
Mecp2loxJ/y/CreER mice (Fig. 6B). At 24
weeks of age, however, the Tam-injected
Mecp2loxJ/y/CreER mice showed signifi-
cant reduction in the number and length of both apical and basal
dendritic branches even when compared with Tam-injected
Mecp2loxJ/y/CreER mice right after injection (6 weeks of age) (Fig.
6B–G). These results suggest that the loss ofMeCP2 in the develop-
ing5-week-oldmicemediated retractionof the already existingden-
dritic arbors. Interestingly, the observed reduced dendritic
complexity was evenmore robust than previously reported for clas-
sic RTT, suggesting a central role for MeCP2 in maintaining the
dendritic complexity of the maturing and mature neurons. Impor-
tantly, analysis of the dendritic spines showed robust reduction (up
to 40%) in spine density of pyramidal neurons of the 5W-Tam-
injected Mecp2loxJ/y/CreER mice at their symptomatic stage when
compared with Veh-injected Mecp2loxJ/y/CreER or Tam-injected
wild-type age-matched littermates (Fig. 6H,I). Furthermore, the as-
sociated dendritic branches showed morphological abnormalities,
such as swelling and thickening (Fig. 6H).
Notably, analysis of the pyramidal neurons of adult 10W-
Tam-injected Mecp2loxJ/y/CreER mice, 18 weeks after injection
(29 weeks of age), showed similar aberrations in basal and apical
dendritic complexity when compared with 10W-Veh-injected
Mecp2loxJ/y/CreER age-matched littermates (Fig. 7A–F). Simi-
larly, comparison of the 10W-Tam-injected Mecp2loxJ/y/CreER
mice, immediately after injection (11weeks of age), whenMeCP2
levels are reduced by 30–40% (data not shown), and at their
symptomatic stage (29 weeks of age), shows dramatic reduction
in both basal and apical dendritic complexity (Fig. 7A–F), further
supporting the idea that dendritic arbors were retracted from a
more mature state in the absence of MeCP2. Similar to the 5W-
Tam-injectedmice, the 10W-Tam-injectedmice showed also sig-
nificant reduction in spine density (Fig. 7H). Furthermore, the
associated dendritic branches showed morphological abnormal-
ities, such as swelling and thickening, similar to the 5W-Tam-
injected mice (Fig. 7G). Together, these data indicate that
inducible loss of MeCP2, whether at late juvenile or adult stage,
mediates dendritic abnormalities, reflected in significant reduc-
tion in dendritic arborization as well as in spine density.
Our previous studies showed that not only neurons, but also
astrocytes contribute to manifestation of RTT neuropathology
(Ballas et al., 2009) (Lioy et al., 2011). Therefore, we asked
whether the morphology of astrocytes is altered upon depletion
ofMeCP2. To this end,we analyzed the processes of hippocampal
astrocytes in the CA1 area in brains that had been subject to
Golgi impregnation. We found that astrocytes of the symp-
tomatic 5W-Tam-injected Mecp2loxJ/y/CreER mice (18 weeks
after injection) had abnormal morphology compared with as-
trocytes of the Veh-injected Mecp2loxJ/y/CreER age-matched
littermates (Fig. 8A), supporting our previous finding of glial
involvement in RTT. While the number of primary processes
radiating from the cell body of astrocytes of symptomatic mice
was not altered, they possessed significantly less ramified pro-
cesses (30% reduction) as assessed by Sholl analysis (Fig. 8B)
and fewer nodes (50% reduction) (Fig. 8C). Moreover, the
average length of processes projected was significantly shorter
(28% reduction) in astrocytes of symptomatic 5W-Tam-
injectedMecp2loxJ/y/CreERmice when compared with astrocytes
of Veh-injected Mecp2loxJ/y/CreER age-matched littermates (Fig.
Figure 8. Processes projected from hippocampal astrocyte cell bodies are severely affected upon the loss of MeCP2 at late
juvenile stage. A, Representative Camera lucida tracing of astrocytes in CA1 area of the hippocampus of symptomatic 5W-Tam-
injectedMecp2loxJ/y/CreER and the 5W-Veh-injectedMecp2loxJ/y/CreER control littermatemice. Concentric circles for Sholl analysis
in 10m radius increments are superimposed in red. Scale bars, 20m. B, Sholl analysis of the 5W-Tam-injected mice showing
that the processes of hippocampal astrocytes at 18 weeks after the last Tam injection (24 weeks of age) are significantly less
complex than those of the 5W-Veh-injectedMecp2loxJ/y/CreER age-matched littermatemice. Two-way repeated-measures ANOVA
followed by appropriate post hoc for multiple-comparisons test was used to determine differences within Veh and Tam groups at
18 weeks after injection. C,D, Hippocampal astrocytes of symptomatic 5W-Tam-injectedMecp2loxJ/y/CreERmice exhibit fewer (C)
and shorter (D) branches at 18 weeks after Tam injection. t test was used to compare between Veh and Tam groups. #p 0.05
significant differences between 5W-Tam and Veh-injectedMecp2loxJ/y/CreERmice at 24 weeks of age (18 weeks after injection).
Error bars are mean SEM. n 3 mice per genotype. n 5 astrocytes per animal.
10030 • J. Neurosci., July 18, 2012 • 32(29):10021–10034 Nguyen, Du et al. •MeCP2 Is Critical for Maintenance of Mature Brain
Figure 9. The loss of MeCP2 at late juvenile and adult stage results in specific reduction of synaptic protein expression in symptomatic Tam-injectedMecp2loxJ/y/CreERmice. A, Western
blot showing significant reduction in the levels of MeCP2, and the following synaptic proteins: CaMKII, CaMKII, GluR2/3, GABABR2, Vglut1, NMDAR2A, and Synapsin 1 in the whole
brain of symptomatic 5W-Tam-injected Mecp2loxJ/y/CreER mice when compared with their levels in the brains of the 5W-Tam-injected Mecp2loxJ/y or the 5W-Veh-injected Mecp2loxJ/y/
CreERmice. B–D, Western blot showing significant reduction in the levels of CaMKII protein in the indicated areas of the brain of symptomatic Tam-injectedMecp2loxJ/y/CreER (3) male
mice injected at 5 (B) or 10 (C) weeks of age, as well as of symptomaticMecp2loxB/y/CreER (3) mice injected with Tam at 5 weeks of age (D). Tam-injectedMecp2loxJ/y orMecp2loxB/y (1) and
Veh-injectedMecp2loxJ/y/CreER orMecp2loxB/y/CreER (2) are control littermates. Actin served as loading control. One-way ANOVA followed by appropriate post hoc for multiple-comparison
tests were used to determine differences between groups. E, Quantitative RT-PCR analysis showing significant reduction in the level of Mecp2 mRNA in whole brain extracts of
symptomatic 5W-Tam-injectedMecp2loxJ/y/CreERmice but no significant differences in the levels of the indicatedmRNAs encoding the specific synaptic proteins when compared with the
mRNA levels in brains of Veh-injected Mecp2loxJ/y/CreER control littermates. t test was used to compare within Veh and Tam groups. Error bars are mean SEM. *p 0.05. n 3 mice
per genotype.
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8D). These data indicate that postnatal
loss of MeCP2 affects the morphology of
neurons as well as glia.
Postnatal loss of MeCP2 affects
expression of both excitatory and
inhibitory synaptic proteins
Finally, we asked whether the reduced
dendritic complexity and spine density
also accompanied alterations in the
amounts of synaptic proteins. To this end,
we analyzed the levels of several known
synaptic proteins with key roles in synap-
tic structure and plasticity. These experi-
ments revealed dramatic reduction, up
to 50%, in the levels of several excitatory
synaptic proteins, such as CaMKII,
CaMKII, and NMDAR2A, as well as the
two synaptic vesicle proteins, Vglut1 and
Synapsin1, and up to 35% in the level of
GluR2/3, in symptomatic Tam-injected
Mecp2loxJ/y/CreER mice when compared
with Tam-injected Mecp2loxJ/y or Veh-
injectedMecp2loxJ/y/CreER littermatemice
(Fig. 9A). Furthermore, the level of
GABABR2, an inhibitory synaptic pro-
tein, was also reduced by up to 40% (Fig.
9A). This reduction in synaptic protein
levelswas not global, but rather specific, as
the levels of the presynaptic protein, Syn-
aptotagmin 1 (Syt1), and the postsynaptic
scaffolding proteins, PSD93 and PSD95,
were not altered (Fig. 9A). We analyzed
more systematically the alteration in
CaMKII, one of the critical synaptic pro-
teins implicated not only in synaptic plas-
ticity but also in stabilization of dendritic
arbor structure. Our results show that the
level of CaMKII protein was dramatically
reduced in all areas of the brains of symptom-
atic 5W-Tam-injected Mecp2loxJ/y/CreER mice, including cortex
and hippocampus (50% reduction), cerebellum, and brainstem (75–
80% reduction) (Fig. 9B). Furthermore, the 10W-Tam-injected
Mecp2loxJ/y/CreERmice exhibited similar reduction (up to 60%) in
CaMKII in all brain areas (Fig. 9C). Importantly, using another
mouse model with different mutation in Mecp2 (Tam-injected
Mecp2loxB/y/CreER; Fig. 2D–F),we found similar dramatic decreases
in the level of CaMKII in all brain areas (Fig. 9D). These data
strongly suggest that the impaired expressionofCaMKII and likely
other synaptic proteins is directly related to the functional loss of
MeCP2. Importantly, when we analyzed the mRNA levels of the
genes whose protein levels were altered, we found no significant
changes (Fig. 9E), suggesting that MeCP2 likely regulates these syn-
aptic proteins by posttranscriptional mechanism, directly or
indirectly.
Discussion
Our results indicate thatRTT-like symptoms,which are causednor-
mally by germline mutations in Mecp2, can be recapitulated if
MeCP2 is lost during the postnatal stage that coincides with the
onset period of classic RTT (late juvenile stage). The immediate on-
set of symptoms in males, as soon as Mecp2 is mutated, and the
severity of symptoms, including death, indicate that MeCP2 func-
tion is critical at this juncture. Interestingly, althoughMeCP2 loss in
heterozygous female mice was induced by tamoxifen at a similar
postnatalstageas inmales, theonsetofsymptomswasdelayeduntil they
were20weeksold, similar to theonsetof symptomsinfemalemicewith
germlinemutations inMecp2. Furthermore, the type of symptoms and
the kinetics of symptom progression and stabilization were similar to
heterozygousfemalemicewithgermlinemutationinMecp2.Thesedata
further support a critical role for MeCP2 at the specific postnatal time
window where RTT symptoms normally appear in males and
females, and further indicate that the absence ofMeCP2 at earlier
stages is not a prerequisite for manifestation of a severe RTT-like
phenotype at later stages. Remarkably, a direct comparison of the
loss of MeCP2 at late juvenile and adult stages showed parallel
onset and progression of RTT symptoms, including the rate of
lethality, and suggested an equal and critical requirement for
MeCP2 function at these two different developmental stages.
Different mechanisms could potentially cause similar RTT-
like symptoms at late juvenile and adult stages or upon the loss of
MeCP2 in germ cells and postnatal stages. However, our detailed
analysis of the brains that lost MeCP2 at postnatal stages suggests
that although the state of brain maturation is different at late
juvenile and adult stages, the loss of MeCP2 mediated similar
brain abnormalities (Fig. 10). The brain abnormalities caused by
Figure 10. Schematic model for the function of MeCP2 during critical stage of postnatal brain development and in the
mature brain. A, During postnatal development, the size and weight of normal brain are increased while neurons mature
as evident by the increase in dendritic complexity and synaptogenesis. The addition of synaptic proteins during late
maturation increases synaptic strength, which in turn increases dendritic branching and stability of dendritic arbor struc-
ture. This process involves neuron:astrocyte interactions. B, In classic RTT caused by germlinemutations inMecp2, the brain
is smaller than normal and neurons exhibit reduced dendritic arborization and synaptic protein expression. C, D, Inactiva-
tion of Mecp2 in otherwise normal mice during their late juvenile period of development (C) or at adult age (D) results in
brain phenotypes typical for classic RTT. However, while the reduced brain size in late juvenile mice is caused partly by
developmental stagnation and partly by shrinkage of the normally developed brain, in adult mice it is caused solely by
shrinkage. In both cases, synaptic protein expression is reduced, and dendritic arbors of the already matured neurons are
retracted. Similar to neurons, the morphology of astrocytes is also altered exhibiting fewer and shorter processes which
together likely affect neuron:astrocyte interactions and therefore disruption of the mature neuronal networks. The loss of
MeCP2, whether due to germline mutations or induced at postnatal stages, during late developmental stage (late juvenile
stage) or adult stage, results in similar brain abnormalities, which lead to RTT phenotypes. E, In the reverse situation, global
reexpression of MeCP2 in symptomatic RTT mice with germline mutation inMecp2 results in reversal of RTT symptoms and
neuronal function (Guy et al., 2007), and postnatal reexpression of MeCP2 in astrocytes inhibits the progression of RTT
phenotypes and restores dendritic arbor structure and the level of at least the synaptic protein Vglut1 (Lioy et al., 2011).
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the loss of MeCP2 at these postnatal stages are comparable in
nature to the abnormalities caused by germline mutations in
MeCP2; however, they are clearly more robust and unequivocal.
These results are surprising because manifestation of similar
brain phenotypes upon loss of MeCP2 in adult brain requires
regression from a more mature state of the brain, as opposed to
developmental stagnation, which is thought to occur in RTT pa-
tients and mouse models with germline mutation in Mecp2. In-
deed, our analysis shows that while the reduced brain size upon
the loss of MeCP2 at a late juvenile stage was due partly to devel-
opmental stagnation and partly to shrinkage; at the adult stage, a
time at which the brain already reached its full size, the reduced
brain size was mediated solely by shrinkage of the brain (Fig. 10).
The increase in neuronal cell packing, which is reciprocal to the
reduced brain size, suggests that shrinkage of the brain is likely
not due to neuronal degeneration. Interestingly, the loss of
MeCP2 in heterozygous female mice elicited shrinkage of their
brain similar to hemizygous male mice, suggesting that evenmo-
saic depletion of MeCP2 in 50% of the cells in the brain is suffi-
cient to affect the brain globally. Our detailed analysis of the
pyramidal neurons in the hippocampus of symptomatic mice
that lostMeCP2 either at late juvenile or adult stage clearly shows
that dendritic complexity was significantly reduced, mainly due
to retraction of dendritic arbors from a more advanced state of
neuronal maturation. Our analysis further shows that dendritic
spine density is dramatically reduced, suggesting that the loss of
MeCP2 in the maturing or mature brain mediates alterations in
synaptic structural plasticity. It is likely that in human RTT pa-
tients andRTTmousemodels, in addition to developmental stag-
nation, shrinking of the maturing brain and retraction of
dendritic arbor structures also take place. This scenario could
explain the regression in RTT girls that manifests in loss of the
already acquired developmental milestones, such as speech and
motor coordination, which may not be simply a consequence of
halting developmental processes, but rather, a result of actual
regression of fundamental anatomical and functional neuronal
features in the brain. Previously, it was shown that RTT symp-
toms can be reversed upon global reactivation of MeCP2 (Guy et
al., 2007) and attenuated by reactivation ofMeCP2 in glia (Lioy et
al., 2011) (Fig. 10). Our present studies, which demonstrate that
RTT-like brain abnormalities could be elicited similarly in nor-
mal adult brain, provide further support for the idea that the
function of MeCP2 in maintaining mature neuronal networks
may be dynamic and that RTT has the potential to be fully
reversed.
Importantly, our structural analysis of the hippocampal astro-
cytes shows that, like neurons, they acquired alteredmorphology
upon the loss of MeCP2 (Fig. 10). Given that astrocytes not only
provide metabolic support to neurons, but are in fact an integral
part of synapses, with their processes ensheathing synapses
(Bolton and Eroglu, 2009), it is not surprising that such alteration
in complexity of astrocytic processes could negatively affect the
structure/function of the entire neuronal networks in the RTT
brain.
Interestingly, our analysis of synaptic protein expression
showed that, of the array of proteins analyzed, few were unal-
tered, more were robustly downregulated, and none were up-
regulated. The selective rather than global downregulation of
synaptic protein expression may indicate that MeCP2 regulates
specific synaptic proteins, directly or indirectly, to upregulate
their expression in the normal maturing or mature brain (Fig.
10). Importantly, none of the geneswhose protein expressionwas
altered showed significant changes in their mRNA expression,
suggesting that either MeCP2 directly regulates these genes post-
transcriptionally, or indirectly by as yet unidentified primary tar-
get genes. These data could also explain why only subtle changes
were mostly observed in mRNA levels in brains of conventional
RTT mouse models (Tudor et al., 2002, Chahrour et al., 2008).
Recent studies show aberrant expression of microRNA genes in a
mouse model of RTT (Urdinguio et al., 2010, Wu et al., 2010). It
is possible that specific microRNAs bind to the mRNAs of these
specific synaptic proteins and inhibit their translation. Among
the synaptic proteins that were downregulated, we identified pre-
synaptic and postsynaptic proteins, both inhibitory and excit-
atory, supporting previous studies demonstrating that specific
loss of MeCP2 in excitatory or inhibitory neurons could initiate
RTT-like phenotypes (Chen et al., 2001, Chao et al., 2010). In
normal brain, dendritic arbor growth is highly dynamic, and ac-
cumulating evidence suggests that synaptic strength and branch
stability are concurrent (Cline and Haas, 2008). Interestingly,
several synaptic proteins, which were dramatically reduced upon
postnatal loss of MeCP2, such as CaMKII, CaMKII, AMPA
receptors (GluR2/3 subunits), and NMDAR2A are involved in
excitatory synapse maturation as well as in increasing and stabi-
lizing dendritic arbor structures (Fink et al., 2003, Haas et al.,
2006). It is likely that the reduction in the levels of these synaptic
proteins upon loss ofMeCP2mediates the retraction of dendritic
arbors.However, we cannot exclude the possibility that the loss of
dendritic arbors and synaptic contacts may trigger the degrada-
tion of proteins localized within these compartments. The effect
of MeCP2 loss on the level of specific synaptic proteins in classic
RTTmouse models remains ambiguous and partially controver-
sial; however, several synaptic proteins that we found downregu-
lated upon postnatal loss of MeCP2 are also downregulated in
RTT mice with germline mutations in Mecp2. Examples are
NMDAR2A (Asaka et al., 2006) and Vglut1 (Chao et al., 2007),
which we also recently showed reduced in a RTT mouse model
and rescued by reactivation of MeCP2 in astrocytes (Lioy et al.,
2011). Similarly, GABAA receptor subunits are downregulated in
classic RTT (Samaco et al., 2005, Medrihan et al., 2008), and our
data showed that GABAB receptor subunit (GABABR2) is also
downregulated as it is in postmortem brain of autistic patients
(Fatemi et al., 2009). It is likely that reduced levels of both
ionotropic andmetabotropic GABA receptor subunits are also
involved in manifestation of RTT symptoms. The reduction in
the levels of synaptic proteins together with the reduction in
dendritic complexity and spine density support the view that
MeCP2 is required during late stages of brain maturation to
establish and maintain mature neuronal circuitry throughout
life (Fig. 10). Although studies using mouse models with
germline mutations in Mecp2 helped to advance our knowl-
edge about RTT development, a mouse model presented here,
which allows to induce loss of MeCP2 at desired timing in
otherwise healthy brain, provides a powerful tool for analyz-
ing the direct effect of MeCP2 loss on brain structure/func-
tion. Further identification of key synaptic proteins and the
mechanism by which MeCP2 regulates these proteins could
provide important insights into the molecular pathways un-
derlying the manifestation of brain abnormalities and identify
new potential targets for therapeutic intervention of RTT.
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